Pfizer and Astellas' XTANDI has been approved by the US FDA for the early treatment of prostate cancer.
XTANDI becomes the first and only androgen receptor signalling inhibitor approved for use with or without GnRH analogue therapy in non-metastatic castration-sensitive prostate cancer.
This approval follows accelerated FDA development and review programs (Priority Review Designation, Fast Track Designation, Real-time Oncology Review), based on the results of the Phase 3 BARK trial.
XTANDI's approval is a promising therapeutic option for the community, offering a glimmer of hope to patients and their caregivers in these challenging times. said Courtney Bugler, President and CEO of ZERO Prostate Cancer.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows:
- primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.;
- specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.;
- oncology products (12.1%);
- other (1.3%).
At the end of 2022, the group had more than 35 manufacturing sites worldwide.
Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).